###### Strengths and limitations of this study

-   This is the largest longitudinal cohort study of ethnic Chinese patients with type 1 diabetes followed for a maximum of 15 years to provide up-to-date incidence estimates of acute and chronic complications.

-   The analyses stratified by gender and age at diabetes onset indicated significant age--gender disparities in the epidemiological data of diabetes-related complications in type 1 diabetes, which highlight importance for clinical attention and developing preventive strategies.

-   The study limitations resulting from the use of medical reimbursement claims data, including potential misclassifications of diabetes-related complications and lack of clinical biomarkers such as blood glucose, may underestimate rather than overestimate the incidence rates of diabetes-related complications.

-   The incidence estimates of diabetes-related complications may only be generalisable to ethnic Chinese population with type 1 diabetes.

Introduction {#s1}
============

It has been estimated that the incidence of type 1 diabetes increases by about 3%--5% per year worldwide.[@R1] The annual incidence rate of childhood (\<15 years) type 1 diabetes in Taiwan was 5.3 per 1 00 000 children in the period 2003--2008.[@R4] Type 1 diabetes accounts for only 5%--10% of the diabetic population, but it remains a devastating chronic disorder with acute complications, including diabetic ketoacidosis (DKA) and hypoglycaemia, chronic complications, which can be divided into microvascular (ie, retinopathy, neuropathy, nephropathy) and macrovascular complications (ie, cardiovascular diseases (CVD)). Although treatment and care for type 1 diabetes have improved,[@R5] diabetes-related complications are major obstacles to glycaemic control for many patients and contribute to most of the increased morbidity and premature mortality in such individuals.[@R8] The toxicity effect of prolonged chronic hyperglycaemia is a leading cause of microvascular and macrovascular diseases among patients with type 1 diabetes, with hypertension and dyslipidaemia being exacerbating factors.[@R9]

Assessing the epidemiology of diabetes-related complications is essential for developing preventive strategies and planning treatment protocols to minimise the impact of the complications. However, there is very little longitudinal data (eg, Pittsburgh Epidemiology of Childhood-Onset Diabetes Complications (EDC) Study,[@R10] EURODIAB IDDM Complications Study[@R11]) on the incidence of complications for type 1 diabetes, and previous estimates widely varied with countries (eg, European countries,[@R12] Finland,[@R13] Denmark,[@R14] USA[@R10]) and entailed different follow-up periods (eg, 7 years,[@R12] 12 years,[@R13] 18 years[@R14] and 30 years[@R10]). In addition, a limited number of diabetes-related complications have been investigated (eg, microalbuminuria[@R12] and CVD[@R13]), with no previous study targeting an ethnic Chinese population with type 1 diabetes. Ethnic variations in diabetes-related complications have been recognised; Caucasian patients are greatly affected by CVD,[@R15] while the prevalence of end-stage renal failure (ESRD)[@R17] and the odds of microalbuminuria and macroaluminuria[@R18] in Asian populations are much higher compared with those for Caucasian patients. Given the significance of rising life expectancy in recent years among ethnic Chinese patients with type 1 diabetes,[@R19] it is important to provide precise up-to-date estimates of incidence of its complications and compare them to those for other countries. We therefore used a longitudinal population-based cohort of patients newly diagnosed with type 1 diabetes who were followed during the period 1999--2013 to evaluate the incidence densities and cumulative incidences of acute and chronic complications to provide contemporary estimates for an ethnic Chinese population. Efforts were also made to examine whether there were age and sex differences in the incidences of type-1-diabetes-related complications.

Materials and methods {#s2}
=====================

The Institutional Review Board of National Cheng Kung University Hospital approved the study before commencement (A-ER-103--298).

Data source {#s2a}
-----------

The present study used the Longitudinal Cohort of Diabetes Patients (LHDB) 1996--2013 data from Taiwan\'s National Health Insurance Research Database (NHIRD). The LHDB is representative of Taiwan's population with diabetes sampled from the beneficiaries in Taiwan\'s National Health Insurance (NHI) programe, which is a mandatory-enrolment and single-payment system that covers over 99% of Taiwan's population.[@R20] The LHDB consists of a random sample of 120 000 deidentified diabetes incident cases enrolled in Taiwan\'s NHI programe from each calendar year, who were tracked back to 1996 and followed up to 2013 to establish a longitudinal cohort. The LHDB is a valid national dataset which has been used in many research that evaluated long-term health outcomes of patients.[@R21]

Cohort {#s2b}
------

From the LHDB, we selected 4677 patients with a diagnosis of type 1 diabetes (International Classification of Diseases, Ninth Revision, Clinical Modification, ICD-9-CM=250.x1 or 250.x3) from outpatient files of the LHDB and having received a Catastrophic Illness Card (CIC) for type 1 diabetes ([figure 1](#F1){ref-type="fig"}) in the period 1999--2012. Because patients with a CIC are eligible for exemption from copayments, the approval of such a status is subject to evaluation and review by the Bureau of NHI of Taiwan. The CIC patient data are accurate and reliable with a positive predictive value of 98.3% for type 1 diabetes.[@R19] We further excluded 670 potential type 2 diabetes cases who consumed any oral antihypoglycaemic agents (OHAs) after CIC was issued, including sulfonylureas, meglitinides, acarbose, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists; however, those who used metformin alone, thiazolidinediones alone or both were retained. Patients who were prescribed metformin, thiazolidinediones or both were retained because these OHAs are insulin-sensitisers that can be combined with insulin treatments for cases with insulin resistance,[@R27] which is also seen in patients with type 1 diabetes in Taiwan based on our expert opinions. To estimate the incidence rates of diabetes-related complications, we further selected cases without a history of the complication before type 1 diabetes diagnosis ([table 1](#T1){ref-type="table"}). Study patients were stratified by gender and age at first type 1 diabetes diagnosis (ie, early onset: 0--12 years, late onset: ≥13 years). The 25^th^, 50^th^ (median) and 75^th^ percentiles of age in early-onset group were 5, 8 and 10 years, respectively, with the mean age of 7.69 years (standard deviation; SD: 3.22). And, for late-onset group, the 25^th^, 50^th^ and 75^th^ percentiles of age were 17, 24 and 33 years, respectively, with the mean age of 26.47 years (SD: 11.60).

![Flowchart of study cohort selection.](bmjopen-2016-015117f01){#F1}

###### 

Overall incidence density of diabetes-related complications among patients with type 1 diabetes between 1999 and 2013

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   Retinopathy       Proliferative retinopathy   STDR           Neuropathy       Nephropathy      Renal failure   CVD            DKA                Outpatient hypoglycaemia   Hospitalised hypoglycaemia
  -------------------------------- ----------------- --------------------------- -------------- ---------------- ---------------- --------------- -------------- ------------------ -------------------------- ----------------------------
  No of cases\*                    3359              3970                        3983           3742             3634             4003            3916           2205               3934                       3987

                                   1532              157                         90             558              688              36              117            996                913                        105

  Follow-up time (person-years)†   15 675            26 733                      27 139         23 320           21 936           27 491          26 664         8224               22 865                     26 968

  Incidence density\               97.74\            5.87\                       3.32\          23.93\           31.36\           1.31\           4.39\          121.11\            39.93\                     3.89\
  (1000 person-years)\             (92.9 to 102.8)   (5.0 to 6.9)                (2.7 to 4.1)   (22.0 to 26.0)   (29.1 to 33.8)   (0.9 to 1.8)    (3.6 to 5.3)   (113.7 to 128.9)   (37.4 to 42.6)             (3.2 to 4.7)
  (95% CI)                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients with type 1 diabetes were retrieved from incident cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrolment from Taiwan's National Health Insurance Programme, or the end of 2013, whichever came first.

\*No of cases refers to the number of patients who had no complication of interest in the baseline year (1 year before diagnosis date).

†No of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

‡Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

CVD, cardiovascular disease, DKA, diabetic ketoacidosis; STDR, sight-threatening diabetic retinopathy.

Diabetes-related complications {#s2c}
------------------------------

The complications of interest included acute complications, namely DKA (confirmed by hospital admission or emergency room visit for DKA), hypoglycaemia (confirmed by defined hypoglycaemic events required for outpatient visits or hospitalisation for medical assistance or interventions) and chronic complications, namely CVD, nephropathy, retinopathy and neuropathy. A list of diabetes-related complications and the corresponding ICD-9-CM codes are provided in online [supplementary table 1](#SP1){ref-type="supplementary-material"}; this list was confirmed by the expert panel before being applied.
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###### Supplementary Table 1

Statistics {#s2d}
----------

The incidence density of diabetes-related complications was calculated by dividing the number of incident cases with individual complication events by the total person-years observed over 15 years of follow-up (1999--2013). The 95% CIs were calculated assuming a Poisson distribution of cases.[@R29] Significant differences in incidence density between age and sex subgroups were indicated by a 95% CI for the difference in incidence density between subgroups.[@R30] Moreover, because a cohort of patients newly diagnosed with type 1 diabetes was used, we were able to provide visual illustrations about the cumulative incidences of diabetes-related complications by diabetes duration since diabetes onset. The cumulative incidence of diabetes-related complications was estimated by using the life table method (using the SAS LIFETEST procedure), and significant difference in cumulative incidence between subgroups was examined according to K-sample tests.[@R31] SAS version 9.4 was used for the aforementioned analyses.

Results {#s3}
=======

The median (25^th^ and 75^th^ percentiles) of the overall follow-up times (defined as the time from diabetes diagnosis to death, loss-to-follow-up, or the end of study period, whichever came first) is 6.74 years (3.43 and 10.02 years). The overall and age--sex-specific incidence densities of diabetes-related complications are presented in [tables 1 and 2](#T1 T2){ref-type="table"}, respectively. The incidence rate of retinopathy (97.74 per 1000 person-years) was greatest, followed by those of nephropathy (31.36), neuropathy (23.93) and CVD (4.39). Among acute complications, the incidence density of DKA was greatest (121.11 per 1000 person-years). As shown in [table 2](#T2){ref-type="table"}, the incidence densities of retinopathy, DKA and hospitalised hypoglycaemia in females were significantly higher than those in males. The incidence densities of DKA and outpatient hypoglycaemia in the early-onset group (0--12 years) were significantly higher than those noted in the late-onset group (≥13 years), while those of advanced retinopathy (ie, sight-threatening diabetic retinopathy; STDR), neuropathy, nephropathy, CVD and hospitalised hypoglycaemia in the late-onset group were significantly higher. [Figures 2 and 3](#F2 F3){ref-type="fig"} show cumulative incidences for acute and chronic complications, respectively, along with diabetes duration. The cumulative incidences at 12years after diagnosis were 52.1%, 36.1% and 4.1% for DKA, outpatient hypoglycaemia and hospitalised hypoglycaemia, respectively. For chronic complications, the 12-year cumulative incidence of retinopathy was greatest (65.2%), followed by those of nephropathy (30.2%), neuropathy (23.7%) and CVD (5.2%). Age--sex-specific cumulative incidences of diabetes-related complications are illustrated in online [supplementary figure 1](#SP2){ref-type="supplementary-material"}.
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###### Supplementary Figure 1

![Cumulative incidences of diabetic ketoacidosis and hypoglycaemia according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95% CI).](bmjopen-2016-015117f02){#F2}

![Cumulative incidences of retinopathy, sight-threatening diabetic retinopathy, neuropathy, nephropathy, renal failure and cardiovascular diseases according to the duration of diabetes in patients with type 1 diabetes (shadow area indicates 95% CI).](bmjopen-2016-015117f03){#F3}

###### 

Incidence density of diabetes-related complications by age at diabetes diganosis and sex among patients with type 1 diabetes between 1999 and 2013

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                 Retinopathy       Proliferative retinopathy   STDR              Neuropathy         Nephropathy        Renal failure    CVD              DKA                Outpatient hypoglycaemia   Hospitalised hypoglycaemia
  ------------------------------------------------------------------------------ ----------------- --------------------------- ----------------- ------------------ ------------------ ---------------- ---------------- ------------------ -------------------------- ----------------------------
  **Male**                                                                                                                                                                                                                                                             

  No of cases†                                                                                                                                                                                                                                                         

  All male                                                                       1618              1886                        1892              1778               1695               1901             1859             1073               1872                       1902

  Early onset (0--12 years)                                                      654               719                         719               714                700                719              712              396                718                        719

  Late onset (≥13 years)                                                         964               1167                        1173              1064               995                1182             1147             677                1154                       1183

  No of cases with event‡                                                                                                                                                                                                                                              

  All male                                                                       693               64                          34                261                332                15               60               447                452                        28

  Early onset                                                                    305               14                          1                 37                 86                 1                7                239                202                        11

  Late onset                                                                     388               50                          33                224                246                14               53               208                250                        17

  Follow-up time (person-years)§                                                                                                                                                                                                                                       

  All male                                                                       7813              12 908                      13 102            11 345             10 403             13 248           12 798           4322               11 025                     13 115

  Early onset                                                                    3333              5290                        5368              5180               4817               5358             5280             1317               4277                       5297

  Late onset                                                                     4480              7618                        7734              6165               5586               7891             7518             3005               6749                       7818

  Incidence density\                                                                                                                                                                                                                                                   
  (1000 person-years)\                                                                                                                                                                                                                                                 
  (95% CI)                                                                                                                                                                                                                                                             

  All male                                                                       88.70\            4.96\                       2.60\             23.01\             31.91\             1.13\            4.69\            103.43\            41.00\                     2.13\
                                                                                 (82.2 to 95.6)    (3.8 to 6.3)                (1.8 to 3.6)      (20.3 to 26.0)     (28.6 to 35.5)     (0.6 to 1.9)     (3.6 to 6.0)     (94.1 to 113.5)    (37.3 to 45.0)             (1.4 to 3.1)

  Early onset                                                                    91.52\            2.65\                       0.19\             7.14\              17.85\             0.19\            1.33\            181.53\            47.23\                     2.08\
                                                                                 (81.5 to 102.4)   (1.4 to 4.4)                (0.0 to 1.0)      (5.0 to 9.8)       (14.3 to 22.0)     (0.0 to 1.0)     (0.5 to 2.7)     (159.2 to 206.1)   (40.9 to 54.2)             (1.0 to 3.7)

  Late onset                                                                     86.60\            6.56\                       4.27\             36.34\             44.04\             1.77\            7.05\            69.22\             37.05\                     2.17\
                                                                                 (78.2 to 95.7)    (4.9 to 8.7)                (2.9 to 6.0)      (31.7 to 41.4)     (38.7 to 49.9)     (1.0 to 3.0)     (5.3 to 9.2)     (60.1 to 79.3)     (32.6 to 41.9)             (1.3 to 3.5)

  95% CI of incidence density difference for male, early vs late onset           −8.5 to 18.3      −6.4 to −1.4\*              −5.9 to −2.3\*    −34.8 to −23.6\*   −33.1 to −19.3\*   −2.8 to −0.4\*   −8.1 to −3.3\*   91.5 to 133.1\*    2.4 to 17.9\*              −1.7 to 1.5

  **Female**                                                                                                                                                                                                                                                           

  No of cases†                                                                                                                                                                                                                                                         

  All female                                                                     1741              2084                        2091              1964               1939               2102             2057             1132               2062                       2085

  Early onset                                                                    721               777                         777               772                764                777              773              413                774                        774

  Late onset                                                                     1020              1307                        1314              1192               1175               1325             1284             719                1288                       1311

  No of cases with event‡                                                                                                                                                                                                                                              

  All female                                                                     839               93                          56                297                356                21               57               549                461                        77

  Early onset                                                                    358               18                          6                 50                 109                1                11               277                229                        21

  Late onset                                                                     481               75                          50                247                247                20               46               272                232                        56

  Follow-up time (person-years)§                                                                                                                                                                                                                                       

  All female                                                                     7862              13 825                      14 037            11 976             11 533             14 243           13 866           3902               11 840                     13 853

  Early onset                                                                    3616              5848                        5910              5610               5283               5927             5871             1183               4642                       5777

  Late onset                                                                     4246              7977                        8127              6365               6250               8317             7995             2719               7199                       8076

  Incidence density (1000 person-years) (95% CI)                                                                                                                                                                                                                       

  All female                                                                     106.72\           6.73\                       3.99\             24.80\             30.87\             1.47\            4.11\            140.69\            38.94\                     5.56\
                                                                                 (99.6 to 114.2)   (5.4 to 8.2)                (3.0 to 5.2)      (22.1 to 27.8)     (27.7 to 34.2)     (0.9 to 2.3)     (3.1 to 5.3)     (129.2 to 153.0)   (35.5 to 42.7)             (4.4 to 6.9)

  Early onset                                                                    99.01\            3.08\                       1.02\             8.91\              20.63\             0.17\            1.87\            234.05\            49.34\                     3.63\
                                                                                 (89.0 to 109.8)   (1.8 to 4.9)                (0.4 to 2.2)      (6.6 to 11.8)      (16.9 to 24.9)     (0.0 to 0.9)     (0.9 to 3.4)     (207.3 to 263.3)   (43.1 to 56.2)             (2.3 to 5.6)

  Late onset                                                                     113.29\           9.40\                       6.15\             38.80\             39.52\             2.40\            5.75\            100.05\            32.23\                     6.93\
                                                                                 (103.4to 123.9)   (7.4 to 11.8)               (4.6 to 8.1)      (34.1 to 44.0)     (34.7 to 44.8)     (1.5 to 3.7)     (4.2 to 7.7)     (88.5 to 112.7)    (28.2 to 36.7)             (5.2 to 9.0)

  95% CI of incidence density difference for female, early onset vs late onset   −28.8 to 0.2      −9.1 to −3.6\*              −7.3 to −3.0\*    −35.5 to −24.2\*   −25.3 to −12.5\*   −3.5 to −1.0\*   −6.0 to −1.7\*   108.4 to 159.6\*   9.8 to 24.4\*              −5.8 to -0.8\*

  95% CI of incidence density difference for male vs female                      −27.8 to −8.2\*   −3.6 to 0.1                 −2.8 to −0.02\*   −5.8 to 2.2        −3.6 to 5.7        −1.2 to 0.5      −1.0 to 2.2      −52.3 to −22.2\*   −3.1 to 7.2                −4.9 to −1.9\*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Patients with type 1 diabetes were retrieved from incident cases from 2000 to 2012. Follow-up time started from the first diagnosis date to the time the event occurred, death, discontinued enrolment from Taiwan's National Health Insurance Programme, or the end of 2013, whichever came first.

\*p\<0.05.

†No of cases refers to the number of patients who had no complication of interest in the baseline year (1 year before diagnosis date).

‡No of cases with event refers to the number of patients who had incident events after type 1 diabetes was confirmed.

§Cumulative follow-up time (person-years) was calculated as the sum of follow-up years during observation period.

CVD, cardiovascular disease, DKA, diabetic ketoacidosis; STDR, sight-threatening diabetic retinopathy.

Discussion {#s4}
==========

To the best of our knowledge, this is the largest cohort study of ethnic Chinese patients newly diagnosed with type 1 diabetes. We provided up-to-date estimates of the incidence of acute and chronic complications in type 1 diabetes patients followed for a maximum of 15 years. We observed age--gender disparities in the incidence of diabetes-related complications in type 1 diabetes. Although comparisons of the epidemiology of diabetes-related complications between studies are difficult, as potential determinants of the complications (eg, age, gender, diabetes duration) differ, the estimates from different studies may reveal some racial or ethnic differences. In the following, we compare our results for ethnic Chinese patients with those reported for other countries or ethnicities.

Acute diabetes-related complications in patients with type 1 diabetes {#s4a}
---------------------------------------------------------------------

### Diabetic ketoacidosis {#s4a1}

Among acute complications, hyperglycaemic events, including DKA and hyperglycaemic hyperosmolar syndrome, are leading causes of morbidity and mortality among individuals with diabetes,[@R32] and use significant healthcare resources.[@R33] DKA was the most common acute complication among the Taiwanese population with type 1 diabetes; the incidence density followed for 15 years was 121.11 per 1000 person-years, and half of the study population (\~52%) experienced DKA at 12 years after diabetes diagnosis. Consistent with previous studies from USA,[@R34] Australia[@R35] and Canada,[@R36] we found that the incidence of DKA in female patients, especially those with early-onset diabetes (ie, 0--12 years), was higher than that in male patients. A cohort of 1234 children with type 1 diabetes in USA showed that female patients were greatly affected by DKA. A female preponderance of DKA was observed in a longitudinal study of childhood type 1 diabetes in Australia.[@R35] Similarly, a Canadian study of childhood type 1 diabetes showed that female sex was a significant predictor of DKA.[@R36] In fact, insulin omission or intentional insulin undertreatment due to fear of weight gain[@R37] and high prevalence of eating disorders[@R38] and psychiatric disorders[@R34] among female patients with type 1 diabetes have been recognised as precipitating causes of DKA. Hence, effective interventions such as health education and communication for females with type 1 diabetes are needed to reduce the incidence of DKA.

Hypoglycaemia {#s4b}
-------------

Increased hypoglycaemic events have been recognised as a result of the undesired effects of intensive insulin therapy with strict glycaemic control.[@R39] The present study showed that the incidence rates of hospitalised and outpatient hypoglycaemia in the Taiwanese population with type 1 diabetes were 3.89 and 39.93 per 1000 person-years, respectively, which are much lower than that reported in type 1 diabetes children (0--19 years) in the USA (incidence of severe hypoglycaemia: 190 per 1000 person-years).[@R34] Such discrepancies in international data may be explained by different definitions and assessment approaches for hypoglycaemic events. We targeted hospital admissions for hypoglycaemia based on ICD-9 CM codes, whereas the US study used patients' reported survey data and classified severe hypoglycaemia as acute episodes requiring the assistance of another person for treatment reported in the preceding 3 months.[@R40]

Moreover, we observed that early-onset patients were greatly affected by acute complications (ie, DKA, hypoglycaemia). It has been documented that, among young children with type 1 diabetes, inconsistent eating patterns and lesser ability to recognise and report acute symptoms make it difficult to achieve glycaemic control, leading to glycaemic fluctuations that cause multiple episodes of hyperglycaemia (ie, DKA) and hypoglycaemia.[@R41] Frequent exposures to hyperglycaemia and hypoglycaemia in early-onset patients with type 1 diabetes could lead to a range of neurocognitive dysfunctions and brain changes.[@R42] Also, structural brain changes in type 1 diabetes children may occur due to recurrent hypoglycaemia.[@R43] Hence, given the high rates of acute complications and associated serious consequences, effective management protocols and identification and treatment of precipitating causes are needed.[@R44] In particular, regular glycaemic monitoring and identification of risk factors in young patients with type 1 diabetes are needed to reduce the frequency and severity of DKA and hypoglycaemia.

Chronic diabetes-related complications in type 1 diabetes {#s4c}
---------------------------------------------------------

### Diabetic retinopathy {#s4c1}

Diabetic retinopathy is the main cause of blindness in the adult population.[@R45] Almost all patients with type 1 diabetes develop evident retinopathy in the first 20 years of diagnosis.[@R46] The present study showed that more than half (\~69%) of the patients with type 1 diabetes experienced some form of diabetic retinopathy at 12 years after diagnosis. We observed that the incidence density of diabetes retinopathy is greatest among chronic complications in Taiwanese patients with type 1 diabetes (4.53 per 100 person-years over a period of 15 years of follow-up). As compared with the incident density of proliferative retinopathy (19.5 per 1000 person-years) in the Pittsburgh EDC Study of patients with type 1 diabetes with a mean age of 28 years and diabetes duration of 19 years at baseline examination,[@R10] our estimate (5.87 per 1000 person-years) based on a cohort of patients newly diagnosed with type 1 diabetes is lower. Such a difference between studies may be explained by diabetes duration and age at baseline of study examination. Moreover, comparing the prevalence of STDR in patients with type 1 diabetes in this study (2.00% for women and 1.66% for men) with that previously observed in Taiwanese patients with type 2 diabetes (2.75% for women and 2.87% for men)[@R47] reveals a slightly lower advanced diabetic retinopathy (ie, STDR) in the patients with type 1 diabetes versus type 2 diabetes. However, the lower rate of STDR in our study may be due to the other study's inclusion of prevalent type 2 diabetes cases with longer diabetes duration[@R47] as compared with incident type 1 diabetes targeted in this study.

Consistent with previous studies,[@R48] the present study demonstrated a female preponderance in diabetic retinopathy. A large cohort of 8114 patients with type 1 diabetes and their families assembled over 25 years from the USA showed that females had 1.7-fold higher retinopathy risk (p\<0.001) when compared with that of males.[@R48] Also, a cross-sectional study of 247 Italian patients with type 1 diabetes showed a significant relationship between diabetic retinopathy and female gender (p=0.01).[@R49] Although exact hormone, genetic, lifestyle or environmental factors are unclear, a differential effect of sex steroid hormones has been proposed to explain this gender discrepancy.[@R50] Also, age at diabetes onset has been shown to be associated with the development of diabetic retinopathy.[@R49] An early age at onset (5--14 years) appears to modify the long-term risk of proliferative retinopathy.[@R51] Consistent with other studies, we observed lower incidence of diabetic retinopathy in early-onset patients as compared with that in late-onset patients. Nevertheless, given a high rate of diabetes retinopathy observed among Taiwanese patients with type 1 diabetes, early detection using routine eye examination, control for risk factors of diabetic retinopathy (eg, hypertension, hyperglycaemia, hyperlipidaemia)[@R9] as well as development of tailored intervention strategies for age--sex subgroups are important.

Diabetic nephropathy {#s4d}
--------------------

Our results show that diabetic nephropathy is the second most common microvascular complication among the Taiwanese population with type 1 diabetes. Without interventions, patients with diabetes with microalbuminuria typically progress to proteinuria and overt diabetic nephropathy.[@R52] Diabetic nephropathy is a leading cause of ESRD among patients with diabetes.[@R52] As estimated, individuals with type 1 diabetes face a 20%--50% chance of developing ESDR that requires dialysis or renal transplantation.[@R53] The Pittsburgh EDC study reported that the incidence density of renal failure (based on self-reported renal transplantation and dialysis) was 6.3 per 1000 person-years over 12 years of follow-up,[@R10] while the present study based on ICD-9 codes of renal failure found that the incidence of renal failure was 1.31 per 1000 person-years over 15 years of follow-up. Of note, the EDC study enrolled more cases with advanced type 1 diabetes (ie, mean age of 28 years and diabetes duration of 19 years at baseline examination[@R10]) than those in our study (ie, cases newly diagnosed with type 1 diabetes in 2000--2012), which may explain the higher rate of renal failure in the EDC study. A large inception cohort study of Danish patients newly diagnosed with type 1 diabetes followed for a median of 18 years reported that the cumulative incidences of persistent microalbuminuria and macroalbuminuria were 33.6% and 14.6%, respectively, while the present study found that overall cumulative incidence of any form of diabetic nephropathy was 30.2% at 12 years after diabetes diagnosis. Moreover, early-onset diabetes appears to be protective for developing diabetic nephropathy[@R12] and may delay the time until microalbuminuria.[@R56] Consistently, we found that  late-onset diabetes patients were more affected by diabetic nephropathy than were early-onset diabetes patients. Nevertheless, given the fact that Taiwan has the highest number of patients undergoing renal dialysis in the world, where diabetes contributes to about 40% of ESRD cases,[@R57] it is critical for routine annual screening of clinical signs of diabetic nephropathy (ie, proteinuria, microalbuminuria), optimal control of blood glucose and relevant risk factors (eg, retinopathy, smoking, dyslipidaemia, hypertension[@R14]), and early intervening medications for prevention (eg, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for those with comorbid hypertension).[@R9]

Diabetic neuropathy {#s4e}
-------------------

Diabetic neuropathy refers to the presence of symptoms, signs or both of peripheral nerve dysfunction in people with diabetes after the exclusion of other causes.[@R60] Peripheral neuropathy in diabetes may manifest in several different forms, including sensory, focal/multifocal and autonomic neuropathies.[@R61] The epidemiological data of diabetic neuropathy are very limited. A study of 467 Italian patients with type 1 diabetes showed that the prevalence rates of asymptomatic and symptomatic neuropathy were 7.2% and 21.3%, respectively.[@R62] The present study is the first study to provide epidemiology data on diabetic neuropathy among ethnic Chinese patients with type 1 diabetes from Asia. We found that the incidence rate was 23.93 per 1000 person-years over 15 years of follow-up, and that the cumulative incidence was 23.7% at 12 years after diabetes diagnosis. We also observed that the incidence of diabetic neuropathy in late-onset patients were much higher than that in early-onset patients. Similarly, the Italian study of type 1 diabetes showed that the prevalence of diabetic neuropathy was higher in patients at older ages.[@R62] Since diabetic neuropathy contributes to considerable disabilities and mortality, it is critical for clinicians to understand its manifestations, prevention and treatment.[@R9] Early prevention strategies that control hypertension and hyperglycaemia and identify patients with peripheral neuropathy or peripheral vascular disease and annual screening for these conditions are strongly recommended.[@R9]

Cardiovascular diseases {#s4f}
-----------------------

CVD is a leading cause of mortality in patients with type 1 diabetes[@R63] and accounts for the greatest proportion of healthcare spending for patients with diabetes.[@R64] As compared with patients without diabetes, type 1 diabetes increases the risk of CVD by 10-fold,[@R63] which contributes to two-thirds of mortality in patients with type 1 diabetes.[@R67] The Pittsburgh EDC study showed an incidence density of 3.6 per 1000 person-years for coronary heart diseases (defined as coronary-artery-disease-related death, a history of myocardial infarction, angiographic stenosis ≥50% including revascularisation) over a period of 12 years,[@R10] while the present study found that the incidence density for a broader category of CVD (including myocardial infarction, ischaemic heart diseases, heart failure, stroke and arrhythmia, as shown in online [supplementary table 1](#SP1){ref-type="supplementary-material"}) in the Taiwanese population with type 1 diabetes within 15 years of follow-up was 4.39 per 1000 person-years. The cumulative incidence of CVD (including only stroke and coronary heart disease) at 12years following diabetes diagnosis was 1%--2% among Finnish patients with type 1 diabetes,[@R13] which is lower than that for the Taiwanese patients with type 1 diabetes observed in the present study (\~5.2%). Moreover, we found that late-onset patients were greatly affected by CVD. In fact, old age is recognised as a predictor of vascular diseases,[@R63] which may be explained by the calcification of extremity arteries and hypertension in older age patients, which are risk factors of macrovascular diseases.[@R69]

Methodological concerns {#s5}
=======================

Some limitations of this study should be acknowledged. The classification of diabetes-related complications based on the ICD-9 CM codes in claims data may underestimate the occurrence of the complications. For example, patients experiencing clinical symptoms/signs of diabetes-related complications (eg, hypoglycaemia) may not see doctors if they can tolerate them. Also, the claims data do not capture clinical/minor symptoms or signs of diabetes-related complications such as minor microalbuminuria. The glycaemic biomarkers such as blood glucose were not available from the claims data, so the identification of hyperglycaemia or hypoglycaemia was only based on the ICD-9 CM diagnosis codes. So, we might underestimate the incidence of hypoglycaemic events and may not be able to disentangle the severity of hypoglycaemia. However, the claims records capture defined diabetes-related complications that are required for medical assistance or treatments, which lead to more conservative estimates and reveal important manifestations of diabetes-related complications for clinical attention. Moreover, based on our operational definition for hospitalised hypoglycaemia (ie, any one of diagnosis codes with hypoglycaemia from the five diagnosis codes in the inpatient files of the NHIRD), two types of hypoglycaemic events could be included: (1) hospital admission for hypoglycaemia and (2) other reasons for hospital admission (eg, DKA), and then hypoglycaemia happened during hospitalisation. It is difficult to differentiate these two types of hypoglycaemic events based on the retrospective claims data we used. However, in the clinical practice in Taiwan, the first code from the five diagnosis codes in hospitalisation is typically to be the main/primary reason for hospital admission. With this regard, we re-run the analyses for hospitalised hypoglycaemia which was identified from the first diagnosis code in hospitalisation. The results are provided in the online [supplementary table 2](#SP1){ref-type="supplementary-material"} and [supplementary figures 2 and 3](#SP3 SP4){ref-type="supplementary-material"}. These re-analytical results may also ease the concern that patients who came to hospital primarily for reasons that may induce hypoglycaemia during hospitalisation. Lastly, the generalisability of our study results may be limited to ethnic Chinese populations. In addition, our results may represent only ethnic Chinese patients with type 1 diabetes in Taiwan.

Conclusion {#s6}
==========

Using an incident cohort of patients with type 1 diabetes diagnosed during the period 1999--2012 with a maximum of 15 years of follow-up, we found that most patients with type 1 diabetes were affected by DKA and retinopathy, which highlight the critical need to identify precipitating causes and modifiable factors for developing preventive strategies and intervening treatment protocols to minimise the impact of these complications. Age and sex discrepancies appear in epidemiological data of diabetes-related complications; late-onset diabetes females were greatly affected by advanced retinopathy (ie, STDR) and hospitalised hypoglycaemia, while early-onset females had a high incidence of DKA. Chronic diabetes-related complications were more common in patients with late-onset of type 1 diabetes, while early-onset individuals were most affected by acute complications. More attention should be given to identify potential risk factors and contributors to such age--sex differences in diabetes-related complications. Population-based data on the incidence of diabetes-related complications from this study are important for clinicians to recognise the need for diagnostic awareness and for policy-makers to develop effective treatments for patients with type 1 diabetes.
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